🐦 推特Wall St EngineCodex · 实盘不做把握 8/10
北京时间·🕒 发布 18:49:26时区推断·⟳ 抓取 18:50:46·⚡ 决策 08-04 19:01:40 +10m54s·83.9 天前
辉瑞二季度收入和调整后EPS超预期，并上调2026年收入指引下限
二季度收入15.0亿美元高于市场预期14.41亿美元，调整后EPS 0.77美元高于预期0.68美元。
📄 原文Wall St Engine@wallstengine↗ 原文
PFIZER $PFE Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $15.0B (Est. $14.41B) 🟢; +3% YoY 🔹 Adj. EPS: $0.77 (Est. $0.68) 🟢; fla…
不做 辉瑞（PFE.US）
同一辉瑞Q2财报和上调全年收入指引下限催化已在内部已处理消息库命中，且本次财报beat/guide raise力度不足以覆盖重复转述风险，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 medium · price-in 风险 medium ↗
关键理由
- 二季度收入15.0亿美元高于市场预期14.41亿美元，调整后EPS 0.77美元高于预期0.68美元。
- 全年收入指引下限从595亿美元上调至605亿美元，但收入和EPS指引中点仍低于或接近一致预期，业绩增量不够强。
- 内部已处理消息库在2026-08-04 10:51 UTC命中同一辉瑞上调全年收入指引下限的催化，重复转述不再出交易卡。
主要风险
- 该条属于财报摘要转述，且同一催化已被系统处理；重复下单会造成同一事件多次暴露。
工具调用 · 历史记录,结果未知(2 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 758 字
PFIZER $PFE Q2’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $15.0B (Est. $14.41B) 🟢; +3% YoY
🔹 Adj. EPS: $0.77 (Est. $0.68) 🟢; flat YoY
Raises FY26 Guide:
🔹 Revenue: $60.5B-$62.5B (Est. $61.79B) 🟡
🔹 Prior Revenue Guide: $59.5B-$62.5B
🔹 Adj. EPS: $2.80-$3.00 (Est. $2.95) 🟡
Segment Net Revenue:
🔹 Biopharma: $14.66B; +2% YoY
🔹 Pfizer CentreOne: $373M; +7% YoY
Other Q2 Metrics:
🔹 Launched & Acquired Products Revenue Growth: +18% Operational
🔹 Revenue Growth Ex-Comirnaty/Paxlovid: +5% Operational
Comments:
🔸 “our obesity program is advancing with meaningful momentum and our oncology portfolio remains a source of strength.”
🔸 “This quarter, I’m particularly pleased with the 18% year-over-year operational revenue growth from our launched and acquired products”
🔹 Revenue: $15.0B (Est. $14.41B) 🟢; +3% YoY
🔹 Adj. EPS: $0.77 (Est. $0.68) 🟢; flat YoY
Raises FY26 Guide:
🔹 Revenue: $60.5B-$62.5B (Est. $61.79B) 🟡
🔹 Prior Revenue Guide: $59.5B-$62.5B
🔹 Adj. EPS: $2.80-$3.00 (Est. $2.95) 🟡
Segment Net Revenue:
🔹 Biopharma: $14.66B; +2% YoY
🔹 Pfizer CentreOne: $373M; +7% YoY
Other Q2 Metrics:
🔹 Launched & Acquired Products Revenue Growth: +18% Operational
🔹 Revenue Growth Ex-Comirnaty/Paxlovid: +5% Operational
Comments:
🔸 “our obesity program is advancing with meaningful momentum and our oncology portfolio remains a source of strength.”
🔸 “This quarter, I’m particularly pleased with the 18% year-over-year operational revenue growth from our launched and acquired products”
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。